MiniMed Group, Inc. (MMED) Key Metrics
MMED valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.92B
- Enterprise value
- $5.57B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.5
- Price / book
- 1.6
- EV / EBITDA
- 92.9
- Dividend yield
- —
- Beta
- —
MMED key metrics, FY2023–FY2026
Fiscal year ended April 30, 2026 · U.S. dollarsMMED returns How much profit the business earns on the capital it uses.
MMED per-share figures Results divided by the shares outstanding at year-end.
MMED financial health Debt, liquidity and how easily interest is covered.
MMED efficiency & capital use Working capital cycle and where the cash goes.
MMED valuation history
MMED returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MMED debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MMED price vs earnings per share
MMED key metrics
FY2023–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $3.17B | — | — | — |
| Enterprise value | $3.01B | — | — | — |
| Price / sales | 1.0 | — | — | — |
| Price / book | 0.9 | — | — | — |
| EV / sales | 1.0 | — | — | — |
| EV / EBITDA | 14.7 | — | — | — |
| Earnings yield | −10.5% | — | — | — |
| Free cash flow yield | −13.3% | — | — | — |
| Share price at fiscal year-end | $12.34 | — | — | — |
| Per share | ||||
| Revenue per share | $12.09 | $9.67 | $8.79 | $7.99 |
| Earnings per share | −$1.29 | −$0.89 | −$0.40 | −$0.34 |
| Operating cash flow per share | −$0.77 | $0.50 | $0.15 | −$0.02 |
| Free cash flow per share | −$1.64 | −$0.19 | −$0.38 | −$0.62 |
| Cash per share | $1.16 | $0.04 | $0.19 | — |
| Book value per share | $14.07 | $11.86 | $12.28 | — |
| Tangible book value per share | $4.87 | $3.37 | $3.68 | — |
| Capex per share | $0.87 | $0.69 | $0.53 | $0.59 |
| Debt per share | $0.57 | $0.04 | $0.03 | — |
| Shares outstanding | 256.6M | 280.8M | 280.8M | 280.8M |
| Change in shares outstanding | −8.6% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −9.5% | −7.4% | −3.2% | — |
| Return on invested capital (ROIC) | 1.1% | −4.7% | −1.6% | — |
| Return on assets (ROA) | −7.5% | −6.0% | −2.7% | — |
| Return on tangible assets | −14.6% | −13.8% | −6.7% | — |
| Free cash flow margin | −13.5% | −2.0% | −4.3% | −7.7% |
| Financial health | ||||
| Total debt | $145.0M | $11.0M | $8.0M | — |
| Cash & short-term investments | $298.0M | $11.0M | $54.0M | — |
| Net debt | −$153.0M | $0 | −$46.0M | — |
| Debt / equity | 0.04 | 0.00 | 0.00 | — |
| Debt / assets | 0.03 | 0.00 | 0.00 | — |
| Net debt / EBITDA | −0.75 | 0.00 | −0.78 | — |
| Current ratio | 1.92 | 1.32 | 1.73 | — |
| Quick ratio | 1.43 | 0.89 | 1.16 | — |
| Working capital | $646.0M | $229.0M | $377.0M | — |
| Invested capital | $3.46B | $3.33B | $3.40B | — |
| Tangible asset value | $1.25B | $945.0M | $1.03B | — |
| Net current asset value | $329.0M | $69.0M | $249.0M | — |
| Graham net-net per share | −$0.23 | −$0.98 | −$0.23 | — |
| Capital allocation | ||||
| Capex / revenue | 7.2% | 7.1% | 6.0% | 7.4% |
| Capex / operating cash flow | — | 137.9% | 361.0% | — |
| Capex / depreciation | 1.43 | 1.35 | 1.15 | 1.45 |
| Stock-based compensation / revenue | 1.5% | 1.5% | 1.5% | 1.6% |
| R&D / revenue | 14.4% | 16.1% | 17.7% | 19.1% |
| SG&A / revenue | 38.1% | 41.7% | 42.8% | 42.8% |
| Efficiency | ||||
| Days sales outstanding | 72.1 | 72.4 | 75.0 | — |
| Days of inventory on hand | 83.5 | 92.3 | 103.3 | — |
| Days payables outstanding | 47.2 | 60.6 | 67.2 | — |
| Cash conversion cycle (days) | 108.4 | 104.1 | 111.0 | — |
| Receivables turnover | 5.06 | 5.04 | 4.87 | — |
| Payables turnover | 7.73 | 6.03 | 5.43 | — |
| Inventory turnover | 4.37 | 3.95 | 3.53 | — |
| Asset turnover | 0.70 | 0.65 | 0.60 | — |
| Average receivables | $612.5M | $538.5M | $507.0M | — |
| Average payables | $184.0M | $197.5M | $190.0M | — |
| Average inventory | $325.5M | $301.0M | $292.0M | — |
| Intangibles / total assets | 51.0% | 56.8% | 59.0% | — |
Computed from MMED's annual financial statements (latest annual report filed June 29, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MMED valuation and financial ratios
MiniMed earned a return on equity of −9.5% and a return on invested capital of 1.1% in fiscal 2026. It ended the year with $145.0 million of debt and $298.0 million in cash and short-term investments, a net cash position of $153.0 million.
See the MMED income statement, the MMED chart for price history, or the MMED stock overview for the latest quote and news.
MMED key metrics FAQ
What is MiniMed's EV/EBITDA?
MiniMed's enterprise value was 14.7 times EBITDA at the end of fiscal 2026 (enterprise value $3.0 billion, EBITDA $205.0 million); the current EV/EBITDA is 92.9.
What is MiniMed's return on equity?
MiniMed's return on equity (ROE) was −9.5% in fiscal 2026: net income of -$331.0 million on average shareholders' equity of $3.5 billion.
What is MiniMed's ROIC?
MiniMed's return on invested capital was 1.1% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does MiniMed have?
MiniMed had total debt of $145.0 million at the end of fiscal 2026, a debt-to-equity ratio of 0.04 and more cash than debt.
What is MiniMed's free cash flow yield?
MiniMed generated -$420.0 million of free cash flow in fiscal 2026, a free cash flow yield of −13.3% on its market value at year-end ($3.2 billion).
What is MiniMed's current ratio?
MiniMed's current ratio was 1.92 at the end of fiscal 2026: current assets were 1.92 times current liabilities.